 Shares of Immix Biopharma Inc. IMMX, 9.20 rocketed 66.0 in premarket trading Monday, after the biopharmaceutical company said its IMX-110 was granted Rare Pediatric Disease RPD designation by the Food and Drug Administration for the threatment of pediatric cancer. The company said IMX-110 is current being evaluated in a Phase 1b2a clinical trial. 